BioCatalystWatch
HUMAWorkspace / HUMA / OverviewCompany library
Price
Market cap
Next catalystExpected 2026CTEV — first-in-human Phase 2a CABG study · Data readoutCompany source ↗
Cash

Chart & Events

Candle interval

Core Clinical

BVP

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

BVP

PreINDP1P2P3FilingApproved
Upcoming / outlook

Other pipelines

Lung

PreINDP1P2P3FilingApproved
HAV

PreINDP1P2P3FilingApproved
HAV

HAV

PreINDP1P2P3FilingApproved
HAV

PreINDP1P2P3FilingApproved
ATEV (Symvess™)

PreINDP1P2P3FilingApproved
CTEV

PreINDP1P2P3FilingApproved
Upcoming / outlook

small-diameter HAV

PreINDP1P2P3FilingApproved
sdATEV

PreINDP1P2P3FilingApproved

Approved / commercial

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

HUMA SEC archive